Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Novembre 2023 - 11:16PM
Business Wire
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
reported the grant in October of non-qualified stock options to
purchase an aggregate of 63,703 shares of Evolus and an aggregate
of 70,320 restricted stock units (RSUs) of the company’s common
stock to 8 newly hired non-executive employees of the company (the
“October Grants”). The Company also is reporting the grant in
November of an aggregate of 64,456 RSUs to 18 newly hired
non-executive employees of the Company (the “November Grants”). The
awards were approved by the compensation committee of the company’s
board of directors under the Evolus’ 2023 Inducement Incentive
Plan, with a grant date and vesting commencement date of October 7,
2023 for the October Grants and November 7, 2023 for the November
Grants, as an inducement material to the new employees entering
into employment with Evolus in accordance with Nasdaq Listing Rule
5635(c)(4).
The stock options in the October Grants have an exercise price
of $8.82 per share, the closing price of Evolus’ common stock on
the trading day preceding the date of grant. The stock options have
a 10-year term and vest over 4 years, with 25% of the number of
shares subject to the option vesting on each annual anniversary of
the vesting commencement date. The RSUs vest 25% on each annual
anniversary of the vesting commencement date. The awards are
subject to the terms and conditions of the 2023 Inducement
Incentive Plan and the terms and conditions of the stock option
agreement or RSU agreement, as applicable, covering the grant,
including requirements to remain continuously employed on each
vesting date.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the
brand name Nuceiva®. The product is manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram
or Facebook.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of
Daewoong Pharmaceutical Co, Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231110714369/en/
Investor Contacts: Ned Mitchell
Arbor Advisory Group Email: ir@evolus.com
Media Contact: Email:
media@evolus.com
Grafico Azioni Evolus (NASDAQ:EOLS)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Evolus (NASDAQ:EOLS)
Storico
Da Mag 2023 a Mag 2024